Targeting the potential of PSMA

Telix’s prostate cancer portfolio targets PSMA (prostate-specific membrane antigen), a protein expressed on the surface of prostate cancer cells, which is low or absent on most normal healthy cells. PSMA has become a major breakthrough in prostate cancer diagnostics and the growing field of nuclear medicine.

High rates of screening in developed countries mean most men are diagnosed and treated early before their disease has spread. These men receive local therapy, either prostatectomy or radiotherapy, and may be cured of their disease. However, approximately 15% of patients develop advanced forms of the disease that can spread to other parts of the body. This is known as metastatic prostate cancer.

Targeted radiation can identify prostate cancer wherever it is in the body and help guide patient treatment.

Prostate cancer worldwide


1.4 million

men were diagnosed with prostate cancer in 2021 globally

375,000+

men died from prostate cancer globally in 2021

34%

increase in prostate cancer diagnoses in Australia during the past 12 months

99%

5-year survival rate for men diagnosed with early-stage prostate cancer in the United States

The antibody approach may deliver superior efficacy, with reduced potential for undesirable side-effects, and a more efficient dosing regimen compared to a small molecule approach. [ref. https://www.onclive.com/view/new-class-of-radiopharmaceutical-therapy-makes-headway-in-prostate-cancer; Sun, Michael et al.. Curr Oncol Rep.]